Loading
Life sciences · Journal article
The Journal of Cardiovascular Nursing · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
BACKGROUND: Obesity-related heart failure with preserved ejection fraction (HFpEF) is characterized by systemic inflammation and reduced functional capacity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve symptoms and weight in randomized trials, but uptake in routine cardiovascular practice is inconsistent. OBJECTIVE: The purpose of this study was to evaluate a structured nurse practitioner-led program for GLP-1 RA initiation in obesity-related HFpEF. METHODS: Prospective 12-month, single-center pre-post effectiveness study at a U.S. urban academic outpatient cardiology clinic. Adults with left ventricular ejection fraction ≥45%, body mass index ≥30 kg/m2, New York Heart Association class II-III symptoms, and at least 1 cardiometabolic comorbidity were enrolled. The intervention included registry-based identification, baseline assessment, patient education, protocolized titration, and longitudinal follow-up. Each participant's 12-month preenrollment period served as a comparator. The primary outcome was GLP-1 RA initiation and 12-month persistence. RESULTS: Of 156 enrolled, 128 (82.1%) completed follow-up. Mean age 67.4 ± 11.2 years; 61.7% female; 43.8% Black. GLP-1 RA use rose from 7.8% to 92.2% (87.5% at target dose). Mean weight decreased 6.2 ± 3.8 kg, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score improved 16.6 ± 11.3 points, and 6-minute walk distance rose 48.3 ± 36.2 m (all P <.001). Systolic blood pressure, hemoglobin A1c (diabetic subgroup), high-sensitivity C-reactive protein, and N-terminal pro-B-type natriuretic peptide all decreased significantly. Heart failure hospitalization fell from 18.2% to 4.7% (P =.002). Gastrointestinal symptoms were most common; 4.7% discontinued for intolerance. CONCLUSIONS: A structured nurse practitioner-led cardiometabolic program was associated with high GLP-1 RA initiation and persistence and with clinically meaningful improvements in symptoms, function, and hospitalization in obesity-related HFpEF.